Provided by Tiger Trade Technology Pte. Ltd.

Nuvectis Pharma, Inc.

23.87
+0.31001.32%
Volume:231.13K
Turnover:5.52M
Market Cap:777.72M
PE:-18.30
High:24.55
Open:23.56
Low:23.34
Close:23.56
52wk High:29.28
52wk Low:5.55
Shares:32.58M
Float Shares:21.23M
Volume Ratio:1.04
T/O Rate:1.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3045
EPS(LYR):-1.3236
ROE:-214.58%
ROA:-73.07%
PB:85.63
PE(LYR):-18.03

Loading ...

Nuvectis Pharma initiated with an Overweight at Cantor Fitzgerald

TIPRANKS
·
Yesterday

Nuvectis Pharma Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Yesterday

Nuvectis Pharma Launches New $200 Million ATM Program

TIPRANKS
·
Aug 22

Nuvectis Pharma files $200M mixed securities shelf

TIPRANKS
·
Aug 22

Nuvectis Pharma Sets up $200 Million At-the-Market Equity Program with Jefferies

Reuters
·
Aug 22

Nuvectis’ NXP800 Ovarian Cancer Trial Terminated: What Investors Should Watch Next

TIPRANKS
·
Aug 07

Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
Aug 06

Nuvectis Pharma: Buy Rating Reiterated as Late-Stage Pipeline Expands and $39 Price Target Remains Unchanged

TIPRANKS
·
Aug 05

Nuvectis Pharma Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 04

Nuvectis Pharma Q2 FY26 Net Loss Widens to USD 7.02 Million

Reuters
·
Aug 04

Nuvectis Pharma Q2 EPS $(0.30) Misses $(0.26) Estimate

Benzinga Earnings
·
Aug 04

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

THOMSON REUTERS
·
Aug 04

Nuvectis Pharma Inc Expected to Post a Loss of 26 Cents a Share - Earnings Preview

Reuters
·
Jul 31

Maxim Group Keeps Their Buy Rating on Nuvectis Pharma (NVCT)

TIPRANKS
·
Jul 24

Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor

TIPRANKS
·
Jul 24

Pantginis Reiterates Buy on Nuvectis, Citing Ciprocopan Approval and Pipeline Diversification; Price Target Maintained at $39

TIPRANKS
·
Jul 23

Nuvectis Pharma Says Paroxysmal Nocturnal Hemoglobinuria Drug Approved by Chinese Regulator

MT Newswires Live
·
Jul 23

Nuvectis Corrects Title of Ciprocopan China Marketing Approval Release

Reuters
·
Jul 23

Nuvectis Pharma receives marketing approval in China for ciprocopan

TIPRANKS
·
Jul 23

Nuvectis Says China Regulator Approves Ciprocopan for Treatment-naive PNH Patients

Reuters
·
Jul 23